According to NCCN guideline, maintenance therapy with PARP inhibitors may benefit for newly diagnosed stage II-IV high-grade serous carcinoma, G2/3 ovarian endometrioid carcinoma, clear cell carcinoma with BRCA1/2 mutation, and carcinosarcoma after CR or PR is achieved following surgery and platinum-based first-line therapy [6]. This evidence concerns the gene BRCA1 and ovarian endometrioid carcinoma.